Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1930–1936. doi: 10.1158/1055-9965.EPI-07-2934

Table 1.

Adverse Events by Category and Dosage

Adverse Event 100 mg n (%) 250 mg n (%) 500 mg n (%) 1,000 mg n (%) 1,500 mg n (%) 2,000 mg n (%)
Total 0 (0) 2 (66.6) 1 (33.3) 3 (50.0) 2 (66.6) 6 (66.6)
Fatigue* 0 (0) 1 (33.3) 0 (0) 1 (16.6) 1 (33.3) 0 (0)
GI Symptoms 0 (0) 0 (0) 1 (33.3) 1 (16.6) 2 (66.6) 4 (44.4)
Headache 0 (0) 1 (33.3) 0 (0) 1 (16.6) 1 (33.3) 1 (11.1)
Other 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 1 (11.1)
*

Fatigue includes: Difficulty Concentrating

GI Symptoms include: Eructation, Heartburn, and Indigestion

Other includes: Decreased Heart Rate and Burning with Urination

**

National Cancer Institute, Common Toxicity Criteria v.2.0